BLT 0.00% 1.6¢ blis technologies limited ordinary shares

Ann: GENERAL: BLT: Some Change To Guidance After Discoloured Product Discovery

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. lightbulb Created with Sketch. 2
    • Release Date: 04/11/15 10:45
    • Summary: GENERAL: BLT: Some Change To Guidance After Discoloured Product Discovery
    • Price Sensitive: No
    • Download Document  2.33KB
    					BLT
    04/11/2015 10:45
    GENERAL
    PRICE SENSITIVE
    REL: 1045 HRS BLIS Technologies Limited
    
    GENERAL: BLT: Some Change To Guidance After Discoloured Product Discovery
    
    4 November 2015
    
    Some Change To Guidance After Discoloured Product Discovery
    
    As a precautionary measure, Blis Technologies Limited halted trading on the
    NZX Monday morning after speckled discolouration in samples of a
    blister-packed lozenge product was discovered in Europe.  Blis Technologies
    is implementing a process to replace the affected product.
    
    This particular formulation was contract manufactured by Blis specifically
    for one European customer.  A quality control investigation has now revealed
    that under extreme humidity some speckling of product is possible.
    Investigations of retention samples held by the company in New Zealand show
    the product remains safe although cosmetically unacceptable.
    
    Europe experienced a particularly hot and humid summer this year and the Blis
    Technologies Research and Development team is now working with the company's
    European distributor to improve the methods of transporting and storage from
    the point of leaving New Zealand to getting to the end consumer.
    Improvements are being implemented in production, quality control and
    logistics.  As a short term solution to meet ongoing demand some lozenges
    will be manufactured in Europe.
    
    The underlying science behind Blis products is unquestioned and backed by
    clinical trials.
    
    The problem does not affect product developed for other markets such as the
    US, Japan, and China.  Products sold in New Zealand such as ThroatGuard,
    FreshBreath, and TravelGuard have a different formulation and are not
    impacted.  Plans for expansion of product sales in Japan and Australia
    scheduled for later this year remain on track.
    
    While some additional costs are expected in terms of replacement of product,
    the board is not revising its revenue guidance, but is making an as yet
    undetermined provision of up to $350,000 against the half year results.
    On October 14, based on prospective half year results, forward orders,
    planned customer product releases and the prevailing exchange rate, Blis
    Technologies revised its revenue guidance for the full year for revenue to
    increase by over 100% to in excess of $5.3m.
    
    BLIS Technologies Limited
    
    Peter Fennessy
    Chairman
    End CA:00272819 For:BLT    Type:GENERAL    Time:2015-11-04 10:45:10
    				
 
watchlist Created with Sketch. Add BLT (NZSX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.